Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03756896 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma | PHASE2 | ACTIVE NOT_RECRUITING | 29 | — | — | Jan 25, 2019 | Jun 30, 2026 | Apr 30, 2025 | 1 | United States |
Completed response (CR) rates will be determined for CPd maintenance.
| Arm | Type | Description |
|---|---|---|
| Carfilzomib, pomalidomide, dexamethasone | EXPERIMENTAL | Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO daily on days 1-21, and dexamethasone PO daily on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| Carfilzomib | DRUG | Given IV |
| Dexamethasone | DRUG | Given PO |
| Pomalidomide | DRUG | Given PO |
Inclusion Criteria: * Patients must meet the following criteria on screening examination to be eligible to participate in the study; all laboratory assessments should be performed within 28 days of initiation of protocol therapy unless otherwise specified; subject is, in the investigator's opinion,...